Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) Short Interest Up 47.5% in June
Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totalling 1,096,000 shares, a growth of 47.5% from the May 30th total of 742,800 shares. Based on an average daily trading volume, of 189,100 shares, the days-to-cover ratio is presently 5.8 days. Approximately 5.5% of the shares of the stock are sold short.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC lifted its stake in Sienna Biopharmaceuticals by 41.6% in the 1st quarter. FMR LLC now owns 4,489,690 shares of the company’s stock worth $10,416,000 after purchasing an additional 1,318,675 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Sienna Biopharmaceuticals during the 1st quarter worth approximately $1,856,000. Golden State Wealth Management LLC acquired a new stake in shares of Sienna Biopharmaceuticals during the 1st quarter worth approximately $419,000. Northern Trust Corp increased its holdings in shares of Sienna Biopharmaceuticals by 2.5% during the 4th quarter. Northern Trust Corp now owns 173,341 shares of the company’s stock worth $402,000 after buying an additional 4,230 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Sienna Biopharmaceuticals by 4.1% during the 4th quarter. Geode Capital Management LLC now owns 168,219 shares of the company’s stock worth $390,000 after buying an additional 6,699 shares during the last quarter. 51.32% of the stock is currently owned by institutional investors and hedge funds.
SNNA traded up $0.01 during trading on Thursday, reaching $0.78. The company’s stock had a trading volume of 67,400 shares, compared to its average volume of 276,020. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.90. The stock has a fifty day simple moving average of $1.08. Sienna Biopharmaceuticals has a 1 year low of $0.72 and a 1 year high of $18.05. The company has a market capitalization of $23.91 million, a P/E ratio of -0.22 and a beta of 2.92.
A number of research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Garrett Motion from a “hold” rating to a “sell” rating in a research note on Wednesday, March 20th. JPMorgan Chase & Co. raised their price target on shares of Vermilion Energy from C$42.00 to C$43.00 in a research note on Monday, May 13th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Sienna Biopharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $21.67.
About Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Further Reading: How is inflation measured?
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.